Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (34,380,295)	$ (81,723,002)	$ (91,940,882)
(Gain) loss on disposal of fixed assets			(19,195)
Change in value of derivatives	(890,362)	301,022	(2,869,267)
Contingent consideration - fair value adjustments		(5,862,464)	1,891,533
Noncash impairment expense		2,050,817
Acquired in-process research and development			10,142,786
Stock-based compensation	7,891,595	11,595,816	10,232,897
Depreciation and amortization	4,690,440	3,260,045	2,336,207
Amortization/(accretion) of note premiums	(43,519)	231,902	1,110,524
Changes in operating assets and liabilities:
Accounts receivable	7,203	(75,000)
Prepaid expenses and Other Current Assets	2,814,509	(1,020,734)	(3,485,421)
Deferred revenue	157,981	5,000,000
Accounts payable	(3,509,995)	2,554,802	2,497,804
Accrued expenses	(401,777)	(871,833)	4,435,784
Other	(274,752)	131,143	(40,385)
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES	(23,938,972)	(64,427,486)	(65,707,615)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	(7,918,198)	(3,860,237)	(1,970,612)
Proceeds from sale of fixed assets			500
Purchases of marketable securities	(44,974,736)
Proceeds from sale of marketable securities	4,248,716	17,308,000	26,090,950
Cash paid for acquisitions			(10,000,000)
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES	(48,644,218)	13,447,763	14,120,838
CASH FLOWS FROM FINANCING ACTIVITIES:
Principal payments on notes payable	(197,790)	(217,549)	(213,991)
Payments of taxes for net share settled restricted stock unit issuances	(438,838)	(634,187)
Proceeds from the exercises of warrants and stock options	272,818	3,752,120	504,512
Proceeds from the issuance of common stock	12,419,119	52,231,433
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES	12,055,309	55,131,817	290,521
NET INCREASE (DECREASE) IN CASH	(60,527,881)	4,152,094	(51,296,256)
CASH AT BEGINNING OF PERIOD	85,366,448	81,214,354	132,510,610
CASH AT END OF PERIOD	24,838,567	85,366,448	81,214,354
Supplementary disclosures:
Interest Paid	(187,647)	(11,287)	(14,429)
Property and equipment purchased through tenant improvement allowance financing		(4,849,360)
Property and Equipment expenditures included in accounts payable and accrued expenses		(4,801,930)
Income Tax Credits Refunded	3,635,016	1,365,288
Income Tax Paid	$ (2,400)	$ (2,400)	(2,400)
Novartis
Supplementary disclosures:
Common Stock issued to Novartis for asset acquisition			$ (25,000,000)